文献速递关节外科骨质疏松与代谢性骨病

骨质疏松患者使用双膦酸盐不增加全膝关节置换术后假体周围骨折风险

Bisphosphonate Use in Patients Who Have Osteoporosis Does Not Increase the Risk of Periprosthetic Fracture Following Total Knee Arthroplasty.
PubMed 文献 · J Arthroplasty · 2024-11-09

本研究基于行政理赔数据库,纳入2010至2019年因骨质疏松行初次全膝关节置换术且有至少2年随访的患者,将术前连续使用双膦酸盐至少6个月者与未使用者按年龄、性别和合并症负担1:1匹配,最终纳入21,058对匹配患者。结果显示双膦酸盐使用不增加假体周围骨折风险(0.7% vs 0.8%,P=0.068;OR 1.24,95%CI 0.99-1.56,P=0.060),但显著降低2年全因翻修风险(OR 0.84,95%CI 0.72-0.97,P=0.021)。

要点

  • 双膦酸盐使用不增加假体周围骨折风险(0.7% vs 0.8%,P=0.068;OR 1.24,95%CI 0.99-1.56,P=0.060)。
  • 双膦酸盐使用者2年全因翻修风险显著降低(OR 0.84,95%CI 0.72-0.97,P=0.021)。
  • 未治疗骨质疏松患者行非骨水泥型全膝关节置换术的假体周围骨折风险高于骨水泥型(1.6% vs 0.4%,P=0.033)。

核心结论

  • 双膦酸盐使用未降低骨质疏松患者全膝关节置换术后假体周围骨折风险,但显著降低2年全因翻修发生率,尽管差异较小。
  • 作者认为,鉴于非骨水泥型假体使用时假体周围骨折率更高,对未经治疗的骨质疏松患者应考虑行骨水泥型全膝关节置换术。

研究设计与样本

  • 基于行政理赔数据库的匹配队列研究,纳入2010至2019年因骨质疏松行初次全膝关节置换术且有至少2年随访的患者。
  • 双膦酸盐使用者定义为术前连续处方双膦酸盐至少6个月,与未使用者按年龄、性别和合并症负担1:1匹配。
  • 排除因慢性糖皮质激素治疗或接受其他骨质疏松药物治疗而行的非择期全膝关节置换术患者,最终纳入21,058对匹配患者。
  • 通过国际疾病分类编码识别术后并发症,并在匹配组间比较,同时按骨水泥型和非骨水泥型全膝关节置换术进行亚组分析。

主要发现

  • 假体周围骨折发生率在单变量分析中为0.7% vs 0.8%(P=0.068),多变量分析OR为1.24(95%CI 0.99-1.56;P=0.060),无差异。
  • 双膦酸盐使用者在2年时全因翻修风险显著更低(OR 0.84,95%CI 0.72-0.97;P=0.021)。
  • 未治疗骨质疏松患者行非骨水泥型全膝关节置换术的假体周围骨折风险高于骨水泥型(1.6% vs 0.4%;P=0.033)。
  • 在接受双膦酸盐治疗的骨质疏松患者中,骨水泥型与非骨水泥型假体的骨折率相当(1.3% vs 1.0%;P=1.000)。

临床怎么用

  • 作者认为,对未经治疗的骨质疏松患者,鉴于非骨水泥型假体使用时假体周围骨折率更高,应考虑行骨水泥型全膝关节置换术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of this study was to evaluate the effect of preoperative bisphosphonate use in patients who have osteoporosis on the risk of complications following primary total knee arthroplasty (TKA). METHODS: An administrative claims database was queried for patients who have osteoporosis undergoing primary TKA between 2010 and 2019 with a minimum of 2-year follow-up. Bisphosphonate-naive patients and bisphosphonate users, defined as patients who had a continuous prescription for bisphosphonates for a minimum of 6 months preoperatively, were matched 1:1 based on age, sex, and comorbidity burden. Patients undergoing nonelective TKA on chronic glucocorticoid therapy or receiving any other pharmacologic treatment for osteoporosis were excluded. The final cohort included 21,058 matched pairs of patients. The incidence of postoperative complications was identified via International Classification of Disease coding and compared between matched groups. A subgroup analysis was performed to examine outcomes among patients who underwent cemented and cementless TKA. RESULTS: There was no difference in the incidence of periprosthetic fracture on univariate (0.7 versus 0.8%, P = 0.068) or multivariate testing (OR [odds ratio]: 1.24, 95% confidence interval [0.99 to 1.56]; P = 0.060). Bisphosphonate users were statistically less likely to undergo all-cause revision TKA at 2 years (OR: 0.84 [0.72 to 0.97]; P = 0.021). Patients who had osteoporosis were found to have an increased risk of periprosthetic fracture when TKA was performed with cementless implants (1.6 versus 0.4%; P = 0.033). However, when treated with bisphosphonates, patients who have osteoporosis demonstrated equivalent fracture rates regardless of implant type (1.3 versus 1.0%; P = 1.000). CONCLUSIONS: While bisphosphonate use in patients who have osteoporosis did not decrease the risk of periprosthetic fracture, it did significantly lower the incidence of all-cause revision at 2 years, although the difference identified was small. Consideration should be given to performing cemented TKA in patients who have untreated osteoporosis, given the higher rate of periprosthetic fracture when cementless implants were utilized.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Forlenza EM, Serino J, Acuña AJ, et al. Bisphosphonate Use in Patients Who Have Osteoporosis Does Not Increase the Risk of Periprosthetic Fracture Following Total Knee Arthroplasty. J Arthroplasty. 2024. PMID: 39528168. doi:10.1016/j.arth.2024.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。